Active Ingredient History
Edetic acid (EDTA) is a chelating agent. The U.S. Food and Drug Administration (FDA) approved edetic acid chelation therapy as a treatment for lead and heavy metal poisoning. Edetic acid in form of disodium salt was withdrawn from the market due to death resulting from hypocalcemia during chelation. NCATS
Drug Pricing (per unit)
Note: This drug pricing data is preliminary, incomplete, and may contain errors.
Organization | Org Type | FDA approvals | Clinical Trials involvement | Org ID | Force Sort |
---|
Organization | Org Type | FDA approvals | Clinical Trials involvement | Org ID | Force Sort |
---|
Acetaminophen (Phase 3)
Chronic Limb-Threatening Ischemia (Phase 3)
Chronic Periodontitis (Phase 4)
Coronary Artery Disease (Phase 3)
Diabetes Mellitus (Phase 3)
Endodontics (Phase 2/Phase 3)
Infections (Phase 2/Phase 3)
Kidney Diseases (Phase 3)
Leukemia (Phase 1/Phase 2)
Leukemia, Lymphocytic, Chronic, B-Cell (Phase 2)
Leukemia, Myeloid, Acute (Phase 2)
Leukemia, Myeloid, Chronic-Phase (Phase 2)
Lymphoma (Phase 1/Phase 2)
Lymphoproliferative Disorders (Phase 1/Phase 2)
Multiple Myeloma (Phase 1/Phase 2)
Myelodysplastic Syndromes (Phase 2)
Myeloproliferative Disorders (Phase 2)
Myocardial Infarction (Phase 3)
Neoplasms (Phase 1/Phase 2)
Periodontitis (Phase 4)
Peripheral Arterial Disease (Early Phase 1)
Renal Insufficiency, Chronic (Phase 4)
Stomatitis, Herpetic (Phase 2)
Trial | Phase | Start Date | Organizations | Indications |
---|
Feedback
Data collection and curation is an ongoing process for CDEK - if you notice any information here to be missing or incorrect, please let us know! When possible, please include a source URL (we verify all data prior to inclusion).
Report issue